Navigation Links
Sleeping Sickness Comes to India

The first case of human trypanosomiasis has now been discovered in India. Sleeping sickness or Human trypanosomiases is endemic in Africa and in South America//, where it is called Chagas disease.

A farmer in India, from the village of Shivani (district of Chandrapur) 140 km from Nagpur in the central State of Maharashtra, has recently been identified as the first confirmed case of human trypanosomiasis recorded in this country.

Human trypanosomiases in Africa is caused by Trypanosoma brucei gambiense and Chagas disease in South America is induced by T. cruzi. In other regions of the world such as India, only animals were up to now known to be infected by certain trypanosomes, which are not pathogenic for humans.

In December 2004, a researcher form the IRD centre in Montpellier, a specialist in the African form of human trypanosomiasis (sleeping sickness), undertook the identification of the pathogenic agent, at the request of the Indian authorities and mandated by the WHO in collaboration with local medical services (1). Morphological examination of parasites contained in the patient’s blood revealed the presence of many trypanosomes belonging to the species T. evansi, which usually infects animals, particularly cattle.

The patient, who had been suffering for several months from recurring bouts of fever, had very high blood parasite count, equal or greater than 106 parasites/ml of blood. Parasitological, serological and molecular analyses confirmed this result. It is the world’s first formally identified case of human trypanosomiasis caused by T. evansi. This trypanosome, which was first identified in 1881 India, in the Punjab, in the horse and Bactrian camel, usually causes a disease called “surra “ in bovines and camel species. Although cases of human carriers of animal trypanosomiases were recorded during that century in India, Sri Lanka and Malaysia, these have either never been formally demonstrated or were only very short-lasting infections.

The patient showed no nervous system damage, indicating an early stage of the disease and the researchers could start treatment. Injections of sodium suramine, a medicine usually used in cases of African T. b. rhodesiense trypanosomiases at the same stage, steadily improved the patient’s health (2).

The patient, who works in permanent contact with animals, had a cut in his hand when he was admitted to the health care centre. Consequently, he was probably infected directly into the bloodstream from an animal infected with T. evansi. However, that does not exclude another indirect, mechanical infection pathway, by way of blood-sucking insect for example. An insect vector is involved in transmission of both sleeping sickness and Chagas disease (3).

Research continues aiming to unravel the transmission process and mechanisms by which the parasite adapts from animal hosts to humans. It should help determine whether or not this first recorded infection of T. evansi trypanosomiasis in humans is an isolated case. Only the recording and diagnosis of other human cases, by indications of the parasite in biological fluids (blood, lymph or cerebrospinal fluid), could signal the disease as an emerging problem. A survey was launched recently to investigate such a possibility. Commissioned by the DGHS (Directorate General of Health Services of Maharashtra), and supported by the WHO and the IRD, it is expected soon to bring data that might shed light on this question.

Source-Eurekalert'"/>




Related medicine news :

1. Sleeping sickness - a silent killer
2. Help For Kids With Difficulty In Sleeping
3. Sleeping Less May be related to Weight Gain
4. Sleeping Boy Does A Rip Van Winkle
5. With New Drug To Fight Against Sleeping, Your Increment Is Not Far Away
6. Uganda Reports Failure To Contain Sleeping Sickness
7. Fluorescent markers to distinguish Trypanosoma brucei strains causing Sleeping Sickness
8. Sleeping Is No Mean Art … It Is A Privilege Denied To Many
9. Toddlers Have Respiratory Trouble When Sleeping With Their Face Up
10. Sleeping disorder risk factor for heart attacks
11. Newer Generation Sleeping Pills Lack Superior Performance
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/22/2017)... ... April 22, 2017 , ... ... as Vice President of Sales and Business Development at OAKWORKS, Inc. Mr. ... engagements, business development, and strategic planning for the company. Recognized industry-wide as ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... An April ... of a pair of ancient teeth, which reveal a great deal about prehistoric ice-age ... a sharp stone may have been used to remove decayed dental matter, and that ...
(Date:4/21/2017)... ... April 21, 2017 , ... The staff at Palm Beach Face is proud to ... in the 2017 London Marathon. Set to take place on April 23rd, the London Marathon ... Dr. Schwartz will run as part of team EMPOWER, raising money for the international charity, ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Chicago plastic surgeon, ... removal of osteoma. An osteoma is a benign bony lump located on the forehead ... and can cause difficulties with sight and pain. Dr. Shah has discovered an approach ...
(Date:4/21/2017)... Wis. (PRWEB) , ... April 21, 2017 , ... ... today announced that its B-595 and B-7569 vinyl label materials ... identification and warning labels are tested to remain intact and legible, for use on ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... ZappRx, Inc ., a digital health company focused on modernizing ... closed $25 million in Series B funding led by Qiming ... Seattle that is part of a broader ... round included participation from SR One , who led ... (formerly Google Ventures). As part of the financing, Mark ...
(Date:4/20/2017)... , April 20, 2017 Research and ... Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 Mn ... by 2024, expanding at a CAGR of 5.6% from 2016 ...
(Date:4/20/2017)... , April 20, 2017 NeuroVive Pharmaceutical ... today announced positive preclinical results demonstrating anti-fibrotic ... for non-alcoholic steatohepatitis (NASH), in an additional ... NV556 has previously shown similar anti-fibrotic ... Today, NeuroVive,s scientists present novel data demonstrating ...
Breaking Medicine Technology: